All updates
All updates
today 49监管与产业动态评分3030 监管与产业动态精选评分4444 Nail detachment over four times more common among GLP-1 users, first controlled study finds
监管与产业动态精选评分6969 Trevogrumab (anti-myostatin) can help preserve lean mass during and after semaglutide-induced weight loss
监管与产业动态评分1717 Lilly raises diabetes weight-loss bar with amylin-Zepbound combo - Fierce Biotech
BioPharma Dive精选评分5757 Bristol Myers trial revisions shake confidence in new class of fibrosis drugs
Endpoints News评分00 AbbVie's eczema drug shows benefit in Phase 2; BioMarin lays off 117
Endpoints News评分00 #EASD26: Lilly's amylin-Zepbound combo posts best-ever weight loss in patients with obesity and diabetes
BioSpace评分5656 Superior weight loss, blood sugar control propel Lilly’s amylin-GIP/GLP-1 combo into Phase 3
STAT News精选评分5757 STAT+: Eli Lilly’s Zepbound combined with amylin drug led to significant weight loss in mid-stage trial
监管与产业动态评分3535 Merck’s anti-TL1A antibody secures a win in ph. 2 hidradenitis suppurativa trial - Fierce Biotech
BioSpace评分4242 Lilly builds commercial case for GLP-1 products over Novo with indirect analyses
监管与产业动态精选评分6262 Experimental obesity drug targets appetite through amylin, offering potential alternative to GLP-1 therapies
监管与产业动态评分2828 Highlight Therapeutics illuminates positive ph. 2 topline data in high-risk skin cancer - Fierce Biotech
监管与产业动态精选评分4949 Connect’s Dupixent rival reduces COPD attacks by 85%, but misses a secondary goal - Fierce Biotech
Nature Medicine精选评分7070 Intravenous hyaluronidase-expressing oncolytic adenovirus with chemotherapy in metastatic pancreatic cancer: a randomized phase 2b trial
NEJM评分00 Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity
监管与产业动态评分3939 Roche, Zealand see phase 2 amylin weight loss peak at mid-dose, start pivotal program - Fierce Biotech
监管与产业动态评分4242 Amgen reveals 6-point drop in lupus severity behind phase 2 win for Horizon antibody - Fierce Biotech
监管与产业动态评分3535 Lilly sets up next-gen obesity battle with full phase 3 retatrutide data - Fierce Biotech
Endpoints News评分3131 #EADV26: Merck shows off mid-stage win for Prometheus drug in skin condition
The Lancet精选评分5656 [Articles] Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial
Endpoints News评分00 #EASD26: Lilly's triple-G allows 60% of patients to drop below obesity threshold
Endpoints News评分00 #EASD26: Zealand and Roche's amylin works best at middle dose, trails Lilly's
Endpoints News精选评分3737 Roche cans muscle-preserving obesity drug, hands it back to Chugai
Endpoints News精选评分5656 Kodiak's stock soars as it clinches crucial Phase 3 win for Eylea competitor
Endpoints News评分1515 Mirum reports Phase 3 victory for acquired hepatitis D med
Endpoints News精选评分3333 Adicet Bio shares promising look at CAR-T for lupus, but stock drops anyway
BioPharma Dive评分4949 UniQure tumbles with latest data for Huntington’s gene therapy
监管与产业动态评分1111 Novo, Lilly pit their GLP-1s against one another in diabetes and obesity as EASD kicks off in Milan - Fierce Pharma
BioSpace精选评分5454 UniQure crashes as Huntington’s gene therapy shows less slowing of disease at 4 years
Endpoints News评分3939 UniQure sinks as Huntington's gene therapy appears to show waning benefit over time
BioSpace精选评分4040 Roche cuts muscle-sparing obesity drug after mid-stage disappointment
监管与产业动态评分2727 uniQure stock crashes as Huntington’s gene therapy data weaken - Fierce Biotech
STAT News评分4444 STAT+: UniQure’s gene therapy continues to slow Huntington’s progression after four years
Nature Medicine精选评分5454 A synthetic lethal drug for microsatellite instability cancers
Nature Medicine精选评分5454 Werner helicase inhibitor for advanced microsatellite instability solid tumors: a phase 1 trial
Nature Medicine精选评分5454 Oral small-molecule GLP-1 receptor agonist safiglipron in early type 2 diabetes: a randomized, double-blind, placebo-controlled trial
The Lancet精选评分6464 [Articles] Efficacy and safety of garetosmab, an activin A-blocking antibody, in fibrodysplasia ossificans progressiva (OPTIMA): a randomised, double-blind, placebo-controlled, phase 3 trial
文献与产业新闻精选评分5454 Kodiak challenges Eylea with a six-month dosing interval in wet AMD
BioPharma Dive精选评分5757 Kodiak skyrockets on positive study data for 2 eye drugs